← Eichor
Study identifier: NCT06838208 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Condition: Extensive-stage Small Cell Lung Cancer (ES-SCLC)  ·  Sponsor: Anhui Provincial Cancer Hospital

PhasePhase 2
Planned participants56
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer

This description comes directly from the study's public registry record.

Talk to the study team

Shuanghu Yuan, PhD  ·  0551-62894008  ·  yuanshuanghu@sina.com

Always discuss trial participation with your own doctor first.

Locations (1)

Anhui Cancer HospitalHefei, Anhui, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06838208